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Abstract 
Lung cancer has become the most commonly diagnosed cancer and the leading cause of 
cancer deaths globally. The major problem of the high mortality rate is the late diagnosis. 
Conventional methods utilized for clinical detection of lung cancer have employed expensive 
and invasive medical procedures that cause stress, discomfort, and pain to patients, and have 
demonstrated low sensitivity, substantial false negatives, and risk of radiation exposure. The 
drawbacks obviate their applicability to large-scale, population-wide screening efforts. This 
paper reviews the applications of using volatile organic compounds (VOCs) in exhaled breath as 
a potential approach for early lung cancer detection. 
An electronic search was conducted in PubMed and Scopus. A total of 41 studies were 
included in this review. The sampling method of exhaled breath employed in most of the 
included studies were leak-proof Tedlar bags. Mass spectrometry and electronic noses were two 
main techniques used in breath sample detection. In the recent years, electronic noses gained 
more popularity due to their portability and cost-effectiveness. In this review, a total of 40 
VOCs, originated from both endogenous and exogenous sources, were found to be significant in 
discriminating between lung cancer patients and healthy controls in two or more of the included 
studies. The included studies demonstrated substantial sensitivity, specificity, and accuracy of 
the method. Overall, the results showed that VOCs in exhaled breath is a promising biomarker 
for early detection of lung cancer. However, the large-scale practice of this method is constrained 
by the lack of standardized breath collection and analysis system and putative exhaled VOC 
biomarkers. Further studies with consistent sampling protocols should be used to demonstrate the 
reproducibility and repeatability of the detection tool before they are applied in clinical practice.
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Lung cancer has become the most commonly diagnosed cancer as well as the leading 
cause of cancer deaths globally, with 2.1 million people diagnosed in 2018 and 1.8 million 
deaths.1 Increases in environmental risk factors are expected to contribute to enhanced number of 
new lung cancer cases. According to the International Agency for Research on Cancer, the 
number of incident cases is estimated to be 2.9 million in 2030, which is 38.1% higher than the 
incident cases in 2018.2  
There are two major types of lung cancer: non-small cell lung cancer (NSCLC) and small 
cell lung cancer (SCLC). Non-small cell lung cancer accounts for 85% of all lung cancer cases 
and can be classified into three histologic types: squamous cell carcinoma, adenocarcinoma, and 
large cell carcinoma.3 Regardless of the histopathological subtype, the five-year mortality rate of 
the lung cancer patients is 88%, suggesting that late diagnosis as a problem.4-6 Early diagnosis of 
lung cancer associates with far better survival than diagnosis at a later stage. The five-year 
survival rate after detection varies between 45% of patients with stage I and 1% of patients with 
stage IV.5 However, the five-year survival rate increases to 60%-80% if diagnosed at early stage.4 
Unfortunately, only 15% of the lung cancer patients are diagnosed at stage I, and more than half 
lung cancer patients die in the first year of being diagnosed.7  
Traditionally, combinations of techniques, such as radiological imaging (i.e., computed 
radiography and computed tomography [CT]), non-radiological imaging (i.e., magnetic 
resonance imaging and automatic fluorescence bronchoscopy), endoscopic (i.e., endocytoscopy) 
and molecular biotechnology, are used to detect lung cancer.6 All these methods are useful at 
various stages of lung cancer diagnosis but are not sufficiently satisfactory for early detection. 
Nearly a quarter of lung cancer patients showed no suspected malignant changes when evaluated 
with chest X-ray, indicating a low sensitivity.8 On the other hand, Zhou et al. reported that if 
purely based on the morphological criteria, it is difficult to distinguish lung cancer from benign 
nodules, which could lead to increased false positives, and resulting unnecessary surgical 
resection procedures.6 Although low dose chest CT screening test was reported to reduce the lung 
cancer mortality by 20%,9 the low positive predictive value (PPV) of CT (2.4% to 5.2%) has 
raised concerns of substantial false positives.10-12 In addition, chest CT is expensive and there are 
risks associated with radiation exposure.9 The potential drawbacks of the existing techniques 
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obviate their applicability to large-scale screening efforts. Therefore, there is an urgent need for 
alternative tools for early lung cancer detection.  
Breath analysis as a screening method for lung cancer has obtained attention in the last 
decades and it is a fast-growing research field. Human exhaled breath contains a mixture of 
hundreds of volatile organic compounds (VOCs).13 These VOCs either enter the body from 
polluted air, food intake, and radiation exposure or produced endogenously by the body itself.14 In 
a healthy individual, the amount of VOCs produced by human metabolism is very low, ranging 
from parts per million to parts per trillion by volume. However, in some diseased conditions (i.e., 
lung cancer), the metabolic functions in body are altered and VOC concentrations are 
significantly changed.15 Therefore, VOCs may reflect the biochemical status and changes of the 
body and provide insight to diseases.  
An initial study by Gordon et al. in 198516 demonstrated the potential of measuring VOCs 
in human breath as a potential for lung cancer screening. The increased prevalence of lung 
cancer has resulted in a recent increase in development of new techniques and methodologies for 
VOC measurement in exhaled breath. As of now, a Tedlar bag is often used to collect exhaled 
breath.17 Mass spectrometry and electronic nose (e-nose) are commonly used tools to detect and 
analyze VOCs in the exhaled breath. The mass spectrometry technique is able to identify the 
specific individual VOCs contained in the breath, whereas an e-nose resembles the function of 
human olfactory organs do with odorants and recognize patterns of VOCs.18 The response of e-
nose when exposed to exhaled breath is usually referred as the smell-print.  
A relatively large number of articles has been published on the topic, however, results of 
the studies have been inconsistent. This up-to-date review is intended to list and rank the 
previously identified VOCs for lung cancer screening among the studies, discuss the potential 
biochemical pathways of altered VOC concentrations in lung cancer patients, compare and 
contrast the spectrometric and e-nose detection methods, and offer suggestions for future 








An electronic search extending back to 1980 was conducted using PubMed and Scopus 
on December 2018 based on the guidelines of PRISMA.19 The main terms used to search for titles 
and abstracts were (exhaled OR breath OR exhalation) and (VOCs OR volatile organic 
compounds) and (lung cancer OR lung carcinoma). Table 1 provides a detailed search strategy 
for each database used. Cross-referencing from the articles found was used to complete the 
search. Inclusion in the systematic review required that a study be 1) original research with 
VOCs detected in human subjects; 2) with at least two groups (i.e., lung cancer patients and 
disease-free controls); 3) lung cancer proved by pathology; and 4) published in English. Studies 
were excluded if they met one of the following criteria: 1) no controls were matched to the lung 
cancer patients; 2) not an original research paper (i.e., case report, review, and systematic 
review/meta-analysis); 3) full text is not written in English; 4) study of lung cancer treatment 
progress or prognosis; and 5) collection and analysis of bronchoscopic air samples. 
For each study, the author, sample collection/extraction/ detection methods, statistical 
analysis method, number of targeted biomarkers, and sensitivity/ specificity/accuracy were 
extracted, if applicable. In this review, the overall sensitivity, specificity and accuracy data from 
the models consisted of a group of VOCs were reported. In some studies, compound-specific 
sensitivity, specificity and accuracy for discriminating between the lung cancer patients and 
controls were reported if the group-specific sensitivity and specificity were not available. 
Sensitivity is the probability that a test correctly classifies those with disease, whereas specificity 
is the probability that a test correctly classifies those without disease. Accuracy is the proportion 
of all subjects who test correctly. They can be calculated as: 
!"#$%&%'%&( = 	 &+,"	-.$%&%'"&+,"	-.$%&%'" + 012$"	#"31&%'" 
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 Single VOC found to be significant in discriminating between lung cancer patients and 





A total of 641 papers were found by using the search strategy discussed above.  After 
removing for duplicates, 480 were remained for abstract and full text screening. During the 
screening process, 430 studies were excluded for not meeting the inclusion criteria, leaving a 
total of 50 studies for full-text review. During the full-text screening, an additional 9 studies 
were excluded, leaving a total of 41 studies16, 20-59 for analysis, as shown in Figure 1. Table 2 lists 
authors and titles of the studies included in this review. 
The included studies represent exhaled breath sample analysis from 10 countries around 
the world, where almost half (18/41) were conducted in the United States or China (nine studies 
from even country, respectively). The sampling method of exhaled breath employed in most of 
the included studies were gas sampling bags (i.e., Tedlar bags). Tedlar bags are leak-proof 
polymer bags with different sizes (in volumes). However, the sampling protocols varied across 
the included studies. Among the 41 studies, 21 collected the alveolar portion of the breath, 19 
collected all portions of exhaled breath, and 1 study did not report the breath collection portion. 
Several studies used a fast response CO2 controlled manner to collect alveolar air samples.  
Different subject preparation practices before breath sample collection were used among 
the included studies. A few studies required the participants to fast overnight for 12 or 24 
hours.20,25,43,46,58 A couple more asked their participants to eat nothing 2 hours before the breath 
test.30 Several studies required each subject to follow the same diet and the same procedure for 
mouth hygiene before sample collection.21,46,56 Three studies asked their participants to refrain 
from eating foods with strong odors, such as garlic, leeks, and onions or any spicy food 24 hours 
before breath sample collection.47,52,58 Although all of the included studies involved smokers, 
only three studies required their participants to stop smoking for 10 or 12 hours before the 
sample collection.43,47,54 Another study asked the study subjects to stop smoking and chewing 
gum prior to the breath sample collection.58  
In order to distinguish between endogenous and exogenous compounds, room/ambient air 
samples were collected as reference in many of the included studies. At the stage of sample 
analysis, a common approach applied was to take the difference between exhaled breath and 
room air to control for the confounding effect of background air. Another two used an approach 
where only VOCs with concentrations at least 10% or 15% higher in exhaled breath than those in 
the ambient air were reported.33,40 One study only included VOCs with amount more than the 
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ambient level.38 A few other studies considered a correlation coefficient > 0.50 between the 
exhaled breath and background air as potential background air pollution. 
Two main techniques were used to detect VOCs from exhaled breath: mass spectrometry 
(n=25) and e-noses (n=16). Among the spectrometric methods, gas chromatography coupled 
with mass spectrometry (GD/MS) was the most commonly used method to detect VOCs in 
exhaled breath samples (n=17). Table 3 summarizes the characteristics of the papers with an 
spectrometry detection technique. Among the 16 studies used e-noses, the sampling system were 
quite different. Six studies used non-selective quartz microbalance (QMC) sensors, 3 studies 
used a handheld portable Cryanose 320, another 3 studies used metal oxide sensors, 2 studies 
used a colorimetric sensor array, and one study used a surface acoustic wave (SAW) sensor 
connected to gas chromatography. Table 4 summarizes the characteristics of the papers with an 
e-noses detection method and Table 5 provides a brief summary of the different types of sensors.  
Lung-cancer specific VOCs can be classified into seven categories: alkanes/alkenes, 
alcohols, aldehydes, ketones, esters, nitriles, and aromatic compounds.60 More than 100 VOCs 
were found in the exhaled breath of lung cancer patients in the included papers. Figure 2 
summarizes the 40 VOCs detected in two or more studies. Among all studies, isoprene and 
propanol were the most commonly detected VOC from exhaled breath found to be significantly 
different between lung cancer patients and healthy subject controls, which was detected in 12/41 
studies respectively. Other frequently detected VOCs included benzene, hexanal, acetone, and 
decane. Among all studies, increased VOC concentrations were observed in lung cancer patients 
as compared to healthy controls, with only a few exceptions.  
Most of the studies reported the sensitivity and specificity data constructed by a group of 
VOCs. The sensitivity ranged from 54% to 100%, and the specificity ranged from 58.6% to 
100%. For mass spectrometry detection methods specifically, the sensitivity ranged from 54% to 
100%, and the specificity ranged from 58.6% to 100%. For the e-nose detection method, the 
sensitivity ranged from 70% to 100%, and the specificity ranged from 72.4% to 100%. However, 
as aforementioned, not all mass spectrometry and sensor systems were the same. The accuracy 
reported from the included studies ranged from 79.6%-100%. 
Most of the studies included in this systematic review did not compare the VOCs in 
exhaled breath from lung cancer patients across different disease stages. Among the studies that 
reported the differences, three studies did not find significant differences in VOCs from exhaled 
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breath in patients at different disease stages.29,34,46 However, Fu et al. reported significantly lower 2-
butanone in exhaled breath of stage I patients, compared to patients with stages II-IV NSCLC. 
Measured 2-butanone concentrations did not differ among stages II-IV patients.44 Ma et al. found 
significantly higher concentrations of exhaled methanol, acetone, propanol, and pentane in 
patients with stage IV than stage IIIb lung cancer. However, the concentration of isoprene in 
exhaled breath did not differ between stage IV and stage IIIb lung cancer patients.47 Using an e-
nose, Gasparri et al. reported a sensitivity of 92% to lung cancer patients with stage I as 
compared to a sensitivity of 58% to pung cancer patients with stages II-IV.52 In a more recent 
study, Oguma et al. found significantly increased cyclohexane and xylene concentrations as the 
clinical stage of lung cancer advanced.55  
  Similar to the lung cancer stages, only several studies compared the differences in 
VOCs in exhaled breath of lung cancer patients with different histological types. Song et al. 
detected a significantly higher concentration of 1-butanol and 3-hydroxy-2-butanone in exhaled 
breath from lung cancer patients with adenocarcinoma compared to those with squamous cell 
carcinoma.34 Wang et al. observed significant concentration differences on 5 VOCs (8-
hexylpentadecane; 3,7-dimethylpentadecane; 8-methylheptadecane; 2-pentadecanone; 5-
propylnonane) between the squamous cell carcinoma group and adenocarcinoma group.43 While 
Fuchs et al. did not observe significant differences in exhaled pentanal, octanal, and nonanal 
concentrations between patients with small cell lung cancer (SCLC) and non-small cell lung 
cancer (NSCLC), patients with SCLC exhaled significantly more hexanal than NSCLC patients.36 
Fu et al. detected a significantly elevated concentration of 4-hydroxyhexenal in exhaled breath 
from lung cancer patients with squamous cell carcinoma than that from adenocarcinoma group.44 
Oguma et al. did not find statistically significant differences in cyclohexane and xylene 
concentrations among lung cancer patients with different histological types.55 
Among the studies that examined the potential confounding effects from age, gender, or 
smoking, almost all found that VOCs profile was independent from these factors, except for a 
few exceptions. Bajtarevic et al. found that isoprene presented age- and gender- specific 
behavior.33 Ulanowska et al. found significantly increased concentrations of acetonitrile, benzene, 





A critical aspect of breath analysis is the collection of the breath samples. Depending on 
the sampling time, portion, and analysis of the study, the profile of VOCs can be greatly 
different. The included studies collected either the total exhaled breath or the alveolar air (at the 
end of the exhaled breath). In human breath, one third of breath are dead-space air from mouth, 
nose, pharynx, trachea, and bronchi, and two-thirds of breath are from the lung alveolar.61 
Previous studies showed that concentrations of VOCs at the end of the exhaled breath can be a 
couple times higher than those from entire exhaled breath,62 and the removal of the dead-space air 
showed enhanced identification of lung cancer by e-nose.63 In addition, due to the fact that the 
exogenous sources of VOCs may alter the VOC concentrations found in the exhaled breath, a 
standardized protocol on subject preparations before the breath sample collection and an 
agreement on the breath portion are crucial. Among all, fasting and smoking are believed to be 
the two major issues associated with exogenous sources of VOCs. Due to the large variability on 
the subject preparations among the included studies, it was difficult to compare the study results 
to one another. 
Two main techniques were used to detect VOCs in exhaled breath: mass spectrometry 
and e-noses. The spectrometric techniques are sensitive and accurate. The main advantage of 
using GC/MS is the ability to identify specific VOC compounds and obtain their concentrations 
in the exhaled breath samples. However, the spectrometric techniques have several drawbacks 
that limit their application in a clinical setting for large population screening. First, the 
spectrometry techniques are comparatively expensive. Second, the technique usually requires 
pre-concentration (i.e., solid phase microextraction [SPME]) before analysis, so it does not offer 
quick and real-time analysis of the breath samples. SPME extraction may be influenced by many 
conditions, including the type of fiber film, extraction time, temperature, and humidity.64 
Depending on the sampling protocol, the accuracy of the analysis could be very different. Third, 
due to the complexity of the operation, trained individuals are required to perform the analysis. 
Fourth, the GC/MS devices are usually not portable. Last, the GC/MS requires constant 
calibration of the analytes.65 
In the recent years, it seems like the researchers are moving to a more portable and cost-
effectiveness method called e-noses. Unlike spectrometry analysis, the goal of e-nose 
measurement is to detect the patterns of VOCs. E-noses are arrays of non-selective sensors that 
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resembles the function of human olfactory organs do with odorants. Non-selective means that 
each sensor is sensitive to a wide range of VOCs, but the sensitivity for each individual 
compound of the sensor array is different. Therefore, it is possible to detect the overall patterns 
of the VOCs.21 The detection of VOCs by e-nose are based on the changes in physical signals, 
such as electrical resistance, oscillation frequency, and color. Compared to the mass 
spectrometry technique, e-nose are portable, cheaper, and able to achieve real-time (or near real-
time) analysis, which is more feasible in clinical settings. While the pattern recognition of e-
noses demonstrated its accuracy in diagnostic assessment in the included studies, spectrometric 
techniques are essential in determining the specific individual VOC to understand their 
pathophysiological pathways and to identify a group of VOCs that are critical in discriminating 
between lung cancer patients and controls. Therefore, at least for now, more studies should be 
done in both GC/MS and e-nose techniques to find the specific VOCs and shape the optimal 
sensors for future use in clinical practice.  
As aforementioned, a total of 40 VOCs in exhaled breath were found to be significantly 
different between lung cancer patients and controls in two or more of the included studies. VOCs 
in exhaled breath could be originated from both endogenous and exogenous sources. At current 
stage, it is still not clear on how the VOCs are linked to the biochemical pathways of lung cancer 
cells. It is hypothesized that lung cancer patients have predisposed, high-risk groups of 
cytochrome p450 enzymes in their body. When exposed to environmental toxins, such as 
tobacco smoke, the enzymes are induced, which potentially modulate the catabolism of the 
VOCs in the body, ultimately leading to detectable changes in VOCs from exhaled breath.66 
Hakim et al.60 have extensively reviewed the evidence of volatile organic compounds of lung 
cancer and possible biochemical pathways. Here, we briefly summarize the potential pathways in 
the context of the relevant VOCs identified from the included papers.  
Alkanes/Alkenes. The main mechanism which affects the production of unbranched 
alkanes/alkenes in the body is oxidative stress. These compounds are produced from lipid 
peroxidation of polyunsaturated fatty acids by reactive oxygen species. Polyunsaturated fatty 
acids are found mainly in cellular and subcellular membranes in the body. Since these fatty acids 
contain multiple double bonds with methylene -CH2- groups, they tend to be peroxidated.60 
Among the branched hydrocarbons, isoprene was the most commonly found VOC. Isoprene is 
believed to be produced non-enzymatically through the mevalonic acid pathway of cholesterol 
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synthesis in the liver.67 While most of the studies found increased concentrations of isoprene in 
lung cancer patients as compared to the controls, two studies reported the opposite findings.29,33 It 
might be explained by the fact that isoprene concentration changes quickly during even minor 
physical effort, such as leg or arm contractions. Therefore, the concentrations of isoprene in 
exhaled breath could be quite different among studies if the sampling protocol were different.60 
Alcohols. Alcohols are mainly originated from food and alcohol beverages in the 
gastrointestinal tract, and metabolism of alkanes by cytochrome p450 enzymes. These alcohols 
can then be metabolized to aldehydes by enzymes in the liver. The unmetabolized alcohols are 
excreted in breath, urine, etc. In the included studies, propanol concentration was found to be 
higher in the exhaled breath of lung cancer patients than the controls. This could be explained by 
the fact of hydroxylation of the lipid peroxidation biomarkers by cytochrome p450 enzymes.60 
Aldehydes. There are four major sources of aldehydes in the body. The first source relates 
to the alcohol metabolism in the liver by group of enzymes, such as alcohol dehydrogenase and 
cytochrome p450 (CYP2E1).60 The second source relates to the secondary product of lipid 
peroxidation by cytochrome p450 enzymes. The third source relates to the cigarette smoke. The 
last source relates to the byproducts of tobacco metabolism by cytochrome p450 during the 
detoxication process.60 In the included studies, the concentrations of seven straight aldehydes 
were found to be significantly higher in the exhaled breath of lung cancer patients, as compared 
to the healthy controls. The elevated levels of aldehydes found in the exhaled breath of lung 
cancer patients could be explained by the increase in aldehyde dehydrogenase activity in the lung 
cancer cell per se or the aldehyde dehydrogenase-2 enzyme mutation.60 
Nitriles. Acetonitrile, a component of tobacco smoke, was the only nitrile found to be 
significant in differentiating between lung cancer and healthy controls in exhaled breath. 
Bajtarevic et al. observed higher acetonitrile concentrations in lung cancer smokers as compared 
to lung cancer ex-smokers.33 In another study, acetonitrile was found to be in higher concentration 
in lung cancer ex-smokers as compared to healthy smokers.37 Some other included studies also 
found higher concentration of acetonitrile in smokers as compared to non-smokers.29 The 
proposed pathways is that acetonitrile is biotransformed into cyanohydrine by cytochrome p450 
monooxygenase, and then decomposes into hydrogen cyanide and formaldehyde. Since 
acetonitrile metabolism is happening very slow in the body, a significant amount of acetonitrile 
is excreted out the body through exhaled breath and/or urine.60 
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Ketones. Ketones are secondary products of lipid peroxidation. For example, acetone, a 
good predictor of ketosis, is formed from the high oxidation rates of fatty acids in lung cancer 
patients as well as with a weight loss. In addition, the formation of acetone and other ketone 
bodies occurs mostly in the final stage of lung cancer, when cachexia occurs.60 Acetone is 
exhaled through breath due to its high vapor pressure. Butanone and pentanone were found to be 
in higher concentrations in the exhaled breath from lung cancer patients compared to the 
controls. Instead of produced endogenously, butanone is believed to be absorbed to the body 
through exogenous sources. 
Aromatic compounds. Aromatic compounds are considered exogenous pollutants 
originated from cigarette smoke, alcohol drinking, air pollution, and radiation exposure. These 
compounds are highly reactive. They may leak into the cytoplasm, posing peroxidative damage 
to proteins, polyunsaturated fatty acids, and DNA, and finally cause damage to biological 
organelles, stimulating cancer. It is believed that the lung cancer patients have absorbed these 
exogenous aromatic compounds in their fatty acids, which then slowly and constantly released 
into the exhaled breath.60 
The sensitivity and specificity reported in the included studies ranged from 54% to 100%, 
and 58.6% to 100%, respectively. For mass spectrometry detection methods specifically, the 
sensitivity ranged from 54% to 100%, and the specificity ranged from 58.6% to 100%. For the e-
nose detection method, the sensitivity ranged from 70% to 100%, and the specificity ranged from 
72.4% to 100%. The accuracy among the reported studies ranged from 82% to 100%. Sensitivity, 
specificity and accuracy are three important measures of the validity of the test results. A high 
sensitivity corresponds to a high negative predicted value (proportion of those test negative do 
not have the disease), which is significant in rule out the individuals. On the contrary, a high 
specificity corresponds to a high positive predictive value (proportion of those test positive 
actually have the disease), which is significant in rule in the patients.68 All the studies should aim 
for the highest sensitivity and specificity if possible. If both cannot be achieved at the same time, 
a high specificity is more desirable than a high sensitivity to avoid excess identification of false 
positive results. False positive results may lead to monetary costs associated with further 
diagnostic tests, psychological stress, discomfort from further diagnostic tests, and burden on 
health care-system.69 
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As stressed in many studies, a single VOC was not enough to discriminate lung cancer 
patients from healthy controls. A group of VOCs were needed to be included in the models to 
achieve substantial sensitivity, specificity, and accuracy. Both endogenous and exogenous could 
be interesting candidates for lung cancer biomarkers. More studies should be done to investigate 
their production mechanisms and clinical value of screening lung cancer. In addition, the wide 
range of VOCs detected in the current studies implies the lack of repeatability and 
reproducibility of the studies. Due to the variation in sampling methods among these studies, a 
standardized method for breath collection and analysis is highly desired in future studies in order 
to achieve easier external comparison. 
There are several limitations of the included studies. One limitation is that well-defined 
groups of ‘pure’ healthy volunteers or patients with specific lung disease were included. 
However, in real life practice, the patients are more heterogeneous, with additional VOCs due to 
complications of lung cancer and other related diseases. Another limitation is the lack of 
comparison of cancer stages and histologic types. Due to relatively small sample sizes, many of 
the included studies were not able to analyze lung cancer subgroups. Concerns still exist on 
whether exhaled breath analysis could detect lung cancer in early stage. At last, as several 
included studies observed significant differences in some of the VOCs concentrations in lung 
cancer patients with different stages or different histologic subtypes, further analyses are much 
needed to verify the existing findings. Standardized multicenter studies with much larger and 
diverse patient populations are necessary. There are also limitations of this systematic review. 
Due to a small number of the included studies reported the information, this review did not 
report the ranges of VOC concentrations detected from the lung cancer patients and healthy 
controls of the included studies. In addition, this review did not take a full in-depth review on the 
statistical analysis used in the studies. There was a large heterogeneity regarding the statistical 
techniques used in the included studies. In future analysis, researches should review the existing 
techniques, and reach a consensus on which data processing techniques should be used. Since the 
objectives of this review were considered to be better answered and understood with qualitative 
analysis, meta-analysis was not done in this review. 
Nevertheless, even with all the limitations, the results suggested that VOCs in exhaled 
breath is a promising tool for early detection of lung cancer in clinical practice. This approach 
fulfills the World Health Organization principles of early disease detection.70 First, lung cancer is 
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an important health problem. It is the most commonly diagnosed cancer and the leading cause of 
cancer death globally. Second, the tumor formation process is relatively complex. The overall 
latency for lung cancer from all types of exposure is rather long. The latency reported to be the 
shortest was lung cancer associated with chromium exposures, which had a minimum of 4 
years.71 Third, the exhaled breath analysis is a relatively practical, efficient and cost-effective 
tool. Breath collection is a simple, rapid, and convenient process that requires minimum efforts 
from the patients. In addition, the sampling process is non-invasive that may be acceptable and 
safe to everyone in the population. Comparing to the existing tests and treatments, exhaled breath 
collection and analysis is also the most cost-effective approach. Included studies had 
demonstrated its high validity that do not identify a large number of false positives. Last, when 
diagnosed with lung cancer, there are accepted treatments available, i.e., chemotherapy, surgery, 
etc. However, further studies should be done is to demonstrate if early detection of lung cancer 
from exhaled breath is truly effective in reducing mortality, as lead-time bias and length-time 
bias are usual concerns in the assessments of survival time in screening studies.72 
 
Conclusions 
Based on the results from this review, exhaled breath analysis in early lung cancer 
detection is an interesting and promising strategy but still constrained by the lack of standardized 
breath collection and analysis system and putative exhaled VOC biomarkers. Therefore, 
considerations for further studies should include: 1) standardize the methods for breath collection 
and analysis; 2) identify a group of VOCs in exhaled breath that is specific to lung cancer; 3) 
compare VOC profiles in lung cancers patients with different stages and histology; and 4) test 
the feasibility and reliability of the practice in larger and more diverse populations. 
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Table 1. Summary of search strategy 
Database Search Strategy Number of References 
PubMed (exhaled[Title/Abstract] OR breath[Title/Abstract] OR 
exhalation[Title/Abstract] OR smell-print[Title/Abstract] 
OR exhalation[MeSH Terms] OR breath tests[MeSH 
Terms]) AND (VOCs[Title/Abstract] OR volatile organic 
compounds[Title/Abstract] OR volatile[Title/Abstract] OR 
chromatography, gas[MeSH Terms] OR electronic 
nose[MeSH Terms]) AND (lung[Title/Abstract] OR lung 
cancer[Title/Abstract] OR lung carcinoma[Title/Abstract] 
OR lung tumor[Title/Abstract] OR lung 




KEY ( breath  OR  exhaled  OR  exhalation )  AND  TITLE-
ABS-KEY ( vocs  OR  "volatile organic 
compounds"  OR  volatile )  AND  TITLE-ABS-
KEY ( "lung cancer"  OR  "lung carcinoma"  OR  "lung 
tumor"  OR  "lung malignancy"  OR  "lung neoplasm" )  
308 
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Candidate articles included for full-text review (n=50) 
Articles included in analysis (n=41) 
Articles excluded on titles and abstracts (n= 430) 
• Irrelevant to the topic of interest  
• Not original research  
• No controls  
• Animal studies 
• Study of treatment response and prognosis 
• Others 
Articles excluded on full-text (n=9) 
• Not written in English 
• No controls 
• Bronchoscopic air sample 
Candidate articles identified after duplicates (n=480) 
Articles identified from PubMed (n=333) Articles identified from Scopus (n=308) 
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Table 2. List of papers included in the analysis 
Author Title Ref. 
Gordon et al.  Volatile organic compounds in exhaled air from patients with lung cancer 16 
Phillips et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study 20 
Di Natale et al. Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors 21 
Phillips et al. Detection of lung cancer with volatile markers in the breath 22 
Machado et al. Detection of lung cancer by sensor array analyses of exhaled breath 23 
Poli et al. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-
term follow-up study 
24 
Yu et al. Solid phase microextraction for analysis of alkanes and aromatic hydrocarbons in human breath 25 
Chen et al. A non-invasive detection of lung cancer combined virtual gas sensors array with imaging recognition technique 26 
Phillips et al. Prediction of lung cancer using volatile biomarkers in breath 27 
Mazzone et al. Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array 28 
Wehinger et al. Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas 29 
Chen et al. A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis 30 
Dragonieri et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD 31 
Westhoff et al. Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung 
cancer: Results of a pilot study 
32 
Bajtarevic et al. Noninvasive detection of lung cancer by analysis of exhaled breath 33 
Song et al. Quantitative breath analysis of volatile organic compounds of lung cancer patients 34 
D’Amico et al. An investigation on electronic nose diagnosis of lung cancer 35 
Fuchs et al. Breath gas aldehydes as biomarkers of lung cancer 36 
Kischkel et al. Breath biomarkers for lung cancer detection and assessment of smoking related effects - confounding variables, 
influence of normalization and statistical algorithms 
37 
Rudnicka et al. Determination of volatile organic compounds as biomarkers of lung cancer by SPME–GC–TOF/MS and 
chemometrics 
38 
Ulanowska et al. The application of statistical methods using VOCs to identify patients with lung cancer 39 
Buszewski et al. Identification of volatile lung cancer markers by gas chromatography-mass spectrometry: comparison with 
discrimination by canines 
40 
Mazzone et al. Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer 41 
Santonico et al. In situ detection of lung cancer volatile fingerprints using bronchoscopic air-sampling 42 
Wang et al. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines 43 
Fu et al. Noninvasive detection of lung cancer using exhaled breath 44 
Handa et al. Exhaled breath analysis for lung cancer detection using ion mobility spectrometry 45 
Zou et al. Optimization of volatile markers of lung cancer to exclude interferences of non-malignant disease 46 
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Ma et al. Determination of breath gas composition of lung cancer patients using gas chromatography/mass spectrometry 
with monolithic material sorptive extraction 
47 
Rudnicka et al. Determination of volatile organic compounds as potential markers of lung cancer by gas chromatography-mass 
spectrometry versus trained dogs 
48 
Phillips et al. Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening 49 
Rocco et al. BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes 50 
Schallschmidt et 
al. 
Comparison of volatile organic compounds from lung cancer patients and healthy controls—challenges and 
limitations of an observational study 
51 
Gasparri et al. Volatile signature for the early diagnosis of lung cancer 52 
Shehada et al. Silicon Nanowire Sensors Enable Diagnosis of Patients via Exhaled Breath 53 
Sakumura et al. Diagnosis by Volatile Organic Compounds in Exhaled Breath from Lung Cancer Patients Using Support Vector 
Machine Algorithm 
54 
Oguma et al. Clinical contributions of exhaled volatile organic compounds in the diagnosis of lung cancer 55 
Li et al. Lung Cancer Screening Based on Type-different Sensor Arrays 56 
Tirzīte et al. Detection of lung cancer in exhaled breath with an electronic nose using support vector machine analysis 57 
Cai et al. A Prediction Model with a Combination of Variables for Diagnosis of Lung Cancer 58 
van de Goor et al. Training and Validating a Portable Electronic Nose for Lung Cancer Screening 59 
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Table 3. Characteristics of the papers included in the review with spectrometry detection method 


























All 20 L  GC/MS Discriminant 
function 
22 VOCs 100%/100% 93.0% 
 
16 








End 10 L GC/MS Forward 
stepwise DA 
+ LOO  














End 1 L GC/MS Forward 
stepwise DA 
+ LOO  
9 VOCs 89.6%/82.9% 
 
N/A 22 








End 150 mL GC/MS Multinomial 
logistic 
regression 
13 VOCs 72.2%/93.6% 82.5% 
 
24 







All N/A GC/MS N/A 5 VOCs N/A N/A 25 










End  1 L GC/MS Fuzzy logic 
model + 
MLR 
16 VOCs 84.6%/80.0% 88.0% 27 
Wehinger et 
al. 





Tedlar bag All 3 L PTR/MS Wilcoxon 
rank sum 
test 

























End 10 mL IMS LDA + LOO 23 VOCs 100%/100% 100% 32 
Bajtarevic et 
al. 







All 3 L GC/MS Kruskal-
Wallis test  
21 VOCs 80%/100% N/A 33 







All 4 L GC/MS Wilcoxon 
rank sum 
test 


















End  10 mL GC/MS Kruskal-
Wallis test  
 



















End 10 mL GC/MS  PCA + 
Mann-
Whitney 
rank test  
42 VOCs N/A N/A 37 
Rudnicka et 
al. 












55 VOCs N/A N/A 38 
Ulanowska et 
al. 







End 500 mL GC/MS DA + 
CHAID 











End 200 mL GC/MS + 
PTR/MS 
Kruskal-
Wallis test  
 
19 VOCs N/A N/A 40 










End 1 L  GC/MS LDA + LOO 23 VOCs 96.5%/97.5% N/A 43 









End 10 mL IMS Decision 
tree 
algorithm 
10 VOCs 76.0%/100.0% N/A 45 








End N/A GC/MS ROC curves 15 VOCs N/A N/A 46 












5 VOCs N/A N/A 47 
Rudnicka et 
al. 








End 1 L GC/MS ANN + 
CHAID 
88 VOCs 74.0%/73.0% N/A 48 

































Gas bulb + 
SPME 
All 1 L GC/MS LDA + LOO 24 VOCs 84.0%/78.0% 81.7% 51 
Sakumura et 
al. 







+ cold trap 
End 1 L GC/MS SVM + 
LOO 
5 VOCs 91.6%/58.6% 89.0% 54 






bag + cold 
trap 
All N/A GC-FID Mann-
Whitney test 









ANN: artificial neural networks; CHAID: chi-squared automatic interaction detector; COPD: chronic obstructive pulmonary disease; 
DA: discriminant analysis; GC-FID: gas chromatography coupled with flame ionization detector; GC/GC-FID: flow-modulated 
comprehensive two-dimensional gas chromatography and flame ionization detector; GC/MS: gas chromatography coupled with mass 
spectrometry; GC-TOF/MS: gas chromatography-time of flight-mass spectrometry; IMS: ion mobility spectrometry; LC: lung cancer; 
LD: lung disease; LDA: linear discriminate analysis; LOO: leave-one-out cross validation; MLR: multilinear regression analysis; N/A: 
not available; NSCLC: non-small cell lung cancer; PCA: principal component analysis; PNMD: pulmonary non-malignant diseases; 
PTR/MS: proton transfer reaction mass spectrometry; ROC: receiver operating curve; SPME: solid-phase microextraction; SVM: 













Table 4. Characteristics of the papers included in the review with e-nose detection method 



















Di Natale et 
al. 










All 1.3 L e-nose PLS-DA + 
LOO  
Profile 100%/94% 90.3% 21 
Machado et 
al. 










All N/A e-nose SVM Profile 71.4%/91.9% 85% 23 









All N/A e-nose ANN 11 VOCs N/A N/A 26 
Mazzone et 
al. 






N/A All N/A e-nose  Random 
forest 
Profile 73.3%/72.4% N/A 28 
Dragonieri et 
al. 





Tedlar bag All N/A e-nose PCA + 
linear CDA 












Tedlar bag End 3 L e-nose PLS-DA + 
LOO 












All N/A e-nose Logistic 
prediction 
models 











2012 Italy N=30; 
20 NSCLC; 
10 controls 
Tedlar bag End 3 L e-nose PLS-DA + 
LOO 
Profile 85.0%/85.0% 85.0% 42 








Tedlar bag All 1 L e-nose Wilcoxon 
rank sum 
test 
4 VOCs 89.8%/81.3% 87.6% 44 








All N/A e-nose  PLS-DA + 
LOO 
Profile 86.0%/95.0% N/A 50 





Tedlar bag End 3 L e-nose PLS-DA + 
LOO 
Profile 81.0%/91.0% N/A 52 









N/A N/A N/A e-nose ANN + 
discriminant 
function  
Profile 87.0%/82.0% 84.0% 53 
Li et al. 2017 China N=52; 
24 LC 
patients; 
5 other LD; 
23 healthy 
controls 
Tedlar bag All 2 L e-nose  LDA-Fuzzy 
5-NN + 
SVM 
Profile  91.6%/91.7% 91.6% 56 
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Tedlar bag All N/A e-nose SVM N/A 98.8%/81.0% 93.0% 57 





Devex bag End 1 L e-nose Mann-
Whitney test 
23 VOCs 76.0%/94.0% 82.8% 58 
van de Goor 
et al. 















AC: asthma and COPD; ANN: artificial neural networks; CDA: canonical discriminant analysis; COPD: chronic obstructive 
pulmonary disease; e-nose: electronic nose; GC: gastric cancer; LC: lung cancer; LD: lung disease; LDA: linear discriminate analysis; 
LOO: leave-one-out cross validation; N/A: not available; NSCLC: non-small cell lung cancer; PLS-DA: partial least square 





Table 5: Summary of different types of e-noses used in the included studies. 
Sensor type Description Reference 
QMB sensors • Non-selective quartz microbalance (QMB) gas sensors, coated with different metalloporphyrins.  
• The VOCs adsorb to the coatings, therefore changing the mass of the quartz crystal and its 
oscillation frequency. 
[21], [35], [42], 
[50], [52], [58] 
Cyranose 320 • A type of conductive polymer gas sensor 
• A handheld portable chemical vapor analyzer, containing a nanocomposite array of 32 carbon-
black polymer sensors.  
• When exposed to VOCs, the sensors swell, thereby changing the electrical resistance, resulting in 
a unique smellprint of differential electrical resistances. 
[23], [31], [57] 
SAW sensors • A pair of surface acoustic wave (SAW) gas sensors coated with poly-isobutylene (PIB) film. 
• When exposed to VOCs, the layer coated on the surface adsorb specific VOCs, leading to mass 
and velocity changes on the surface, which could be monitored by counting the frequency of the 
sensor. 
[26] 
Colorimetric • A colorimetric sensor array contains 36 chemically sensitive spots impregnated on a disposable 
cartridge. 
• Each spot has different sensitivities to VOCs. The colors of these spots change based on the 
chemicals with which they come into contact. 
[28], [41] 
Metal oxide sensors • Types: silicon microreactors and Aeonose. 
• Silicon microreactors are composed of a ceramic support tube coated with silicon oxide 
micropillars. 
• Aeonose consists of three micro hotplate metal oxide sensors with different surface properties. 
• Redox reactions of the VOCs at the surfaces of the metal oxide sensors induce conductivity 
change of the sensors. 
[36], [53], [59] 
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Figure 2: Summary of volatile organic compounds groups detected in two or more studies 
 
 
 
